TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

KeifeRx Expands Exclusive Licensing Agreement with Georgetown University to Cover Multiple Disease Indications for Unique Tyrosine Kinase Inhibitors

Tuesday, January 09, 2024

KeifeRx, an emerging clinical-stage biopharmaceutical company focused on discovering and developing novel treatment options for neurodegenerative and immune diseases, announced today an amended exclusive licensing agreement with Georgetown University. This collaboration aims to advance the development of tyrosine kinase inhibitor (TKI) chemical entities (NCE) for treating various disease indications.

Under the revised agreement, KeifeRx gains an extension of exclusively licensed rights for four chemical entities—KFRX03, KFRX04, KFRX05, and KFRX06. Initially designed for neurodegenerative diseases, these compounds are now being explored for new conditions, including inflammatory diseases, mast-cell associated diseases, and oncology. The exclusive rights cover the development of these compounds through 2037.

KeifeRx is currently conducting optimizing and IND-enabling studies on the four TKI formulations, with a focus on leveraging their potential in addressing a broad spectrum of diseases.

Early-stage clinical trials at Georgetown University, along with preclinical research led by KeifeRx's co-founder, Dr. Charbel Moussa, demonstrated the ability of TKIs to penetrate the brain, induce autophagy, and facilitate the removal of disease-causing toxic proteins, showcasing promise in neurodegenerative disease treatment. Additionally, these TKIs have shown potential in targeting mast cells and modulating both peripheral and central immunity, offering therapeutic possibilities for various immune diseases.

Chris Hoyt, Chief Executive Officer of KeifeRx, emphasized the significance of the expanded licensing agreement, stating, "This collaboration with Georgetown is a pivotal milestone for the growth of KeifeRx. It significantly broadens the range of indications we can pursue with our portfolio of TKIs, encompassing neurodegenerative, neuroinflammatory, and mast cell-related diseases."

Hoyt added, "We are excited about collaborating with the research team at Georgetown University to advance the development of these TKIs for the treatment of multiple underserved disease indications. With intellectual property protection extending through 2037, our portfolio represents a high-value drug opportunity, addressing potential diseases such as Alzheimer's, ALS, mast cell activation syndrome (MCAS), and urticaria."

 

Source: prnewswire.com

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit